EZH2 and myeloid neoplasm: Gu et al. showed that BCAT1, which catalyzes the reversible transamination of branched-chain amino acids, is aberrantly activated in EZH2-deficient myeloid neoplasms, and inhibition of BCAT1 selectively impairs EZH2-deficient cells.